Alector, Inc.
ALEC · XNASCIK 1653087fmd_0C17V3XQZ70Z0E6BPGJX47CZNFManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 36 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 4 | 28 | 21 | 21 | 207 | 134 | 97 | 101 | 21 |
| Research and development | 30 | 73 | 101 | 157 | 189 | 210 | 192 | 186 | 123 |
| Total operating expenses | 36 | 85 | 136 | 216 | 244 | 271 | 249 | 246 | 177 |
| Compensation and benefits | – | – | – | – | – | 69 | 73 | 73 | 52 |
| Operating income | (33) | (57) | (114) | (195) | (37) | (138) | (152) | (145) | (156) |
| Other non-operating income (expense) | 0 | 5 | 9 | 5 | 1 | 8 | 27 | 26 | 13 |
| Income before taxes | – | – | – | – | – | (130) | (125) | (119) | (143) |
| Income tax expense | – | – | 0 | 0 | 0 | 3 | 5 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | (133) | (130) | (119) | (143) |
| Net income | (32) | (52) | (105) | (190) | (36) | (133) | (130) | (119) | (143) |